Agile Therapeutics, Inc. (AGRX)
OTCMKTS: AGRX · Delayed Price · USD
0.370
+0.002 (0.61%)
Apr 18, 2024, 3:56 PM EDT - Market closed

Company Description

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States.

Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch.

The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.

Agile Therapeutics, Inc.
Agile Therapeutics logo
Country United States
Founded 1997
IPO Date May 23, 2014
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 19
CEO Alfred F. Altomari

Contact Details

Address:
500 College Road East, Suite 310
Princeton, New Jersey 08540-6635
United States
Phone 609-683-1880
Website agiletherapeutics.com

Stock Details

Ticker Symbol AGRX
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001261249
CUSIP Number 00847L100
ISIN Number US00847L3087
SIC Code 2834

Key Executives

Name Position
Alfred F. Altomari Chairman, President and Chief Executive Officer
Geoffrey P. Gilmore Senior Vice President and Chief Administrative Officer
Dr. Paul Korner M.B.A., M.D. Senior Vice President and Chief Medical Officer
Scott M. Coiante Chief Financial Officer, Senior Vice President and Treasurer
Matthew Riley Head of Investor Relations and Corporate Communications
Robert G. Conway M.E. Senior Vice President and Chief Corporate Planning and Supply Chain Officer
Amy Welsh Senior Vice President and Chief Commercial Officer

Latest SEC Filings

Date Type Title
Apr 9, 2024 8-K Current Report
Mar 28, 2024 10-K Annual Report
Mar 28, 2024 8-K Current Report
Mar 25, 2024 8-K Current Report
Mar 14, 2024 8-K Current Report
Feb 23, 2024 424B5 Filing
Feb 23, 2024 424B5 Filing
Feb 23, 2024 8-K Current Report
Feb 15, 2024 8-K Current Report
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals